Prevalence and Susceptibility Pattern of Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa in Karachi.

Pakistan journal of medical sciences (2014-09-17)
Fouzia Khan, Adnan Khan, Shahana Urooj Kazmi
RESUMEN

To determine the frequency and susceptibility pattern of multi-drug resistant (MDR) Pseudomonas aeruginosa isolated from clinical specimens in Karachi. This cross sectional study was conducted in Microbiology Department, University of Karachi, from January 2012 to January 2013. Clinical specimens were collected from different hospitals of Karachi. Clinical isolates were identified by standard and specific microbiological methods. The antibiotic susceptibility pattern was determined by Kirby Bauer Disc diffusion method. Clinical and Laboratory Standards Institute (CLSI) guidelines were used to determine the results. The frequency of MDR P. aeruginosa isolated from different clinical specimens was found to be 30%. Amikacin was found to be the most effective antibiotic, followed by Co-trimaxazole and Quinolones. Antibiotic resistant P. aeruginosa are emerging as a critical human health issue. There is an urgent need to resolve the issue by taking some preventive measures. Combined efforts of health care professionals and researchers are required to educate people about the proper use of antibiotics and other infection control measures.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Nalidixic acid, ≥98%
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
USP
Meropenem, United States Pharmacopeia (USP) Reference Standard
Supelco
Cefuroxime, VETRANAL®, analytical standard
Cystine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Cystine
USP
Piperacillin, United States Pharmacopeia (USP) Reference Standard
USP
Cystine, United States Pharmacopeia (USP) Reference Standard
USP
Amikacin, United States Pharmacopeia (USP) Reference Standard
Piperacillin, European Pharmacopoeia (EP) Reference Standard
Nalidixic acid, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.